sorafenib has been researched along with tyrphostin ag 1024 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tyrphostin ag 1024) | Trials (tyrphostin ag 1024) | Recent Studies (post-2010) (tyrphostin ag 1024) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 89 | 0 | 52 |
| Protein | Taxonomy | sorafenib (IC50) | tyrphostin ag 1024 (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 1.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
1 other study(ies) available for sorafenib and tyrphostin ag 1024
| Article | Year |
|---|---|
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, IGF Type 1; Sorafenib; Tumor Cells, Cultured; Tyrphostins | 2007 |